Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) [QOL]
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Bladder Cancer
- Sponsor
- University of Birmingham
- Enrollment
- 2700
- Locations
- 1
- Primary Endpoint
- Quality of life as measured by EORTC QLQ-C30, QLQ-BLS24, and QLQ-BLM30 questionnaires
- Last Updated
- 12 years ago
Overview
Brief Summary
RATIONALE: Studying quality of life in patients with bladder cancer may help determine the long-term effects of bladder cancer and may help improve the quality of life for patients in the future.
PURPOSE: This clinical trial is studying quality of life in patients with bladder cancer.
Detailed Description
OBJECTIVES: * To study the effects of recurrence and progression on health-related quality of life (HRQL). * To study the effects of repeat cystoscopy on HRQL. * To study the patients' assessments of a hypothetical prognostic model and how this affects their preference for the mode of surveillance. OUTLINE: This is a multicenter study. Quality-of-life questionnaires developed by the European Organization for Research and Treatment for Cancer (EORTC) will be used. The EORTC QLQ-BLS24 with 24 questions specific to non-muscle-invasive bladder cancer and the EORTC QLQ-BLM30 with 30 questions specific to muscle-invasive bladder cancer will be combined and used in conjunction with the general cancer questionnaire QLQ-C30. Assessments using the QLQ-C30 will be made at baseline in the entire cohort of patients. Follow-up assessments using the QLQ-C30, QLQ-BLS24, and QLQ-BLM30 167 will be made at first routine follow-up and annually until the end of study. Peer Reviewed and Funded or Endorsed by Cancer Research UK.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Quality of life as measured by EORTC QLQ-C30, QLQ-BLS24, and QLQ-BLM30 questionnaires